Home Medicine A pilot study of new promising non-coding RNA diagnostic biomarkers for early-stage colorectal cancers
Article
Licensed
Unlicensed Requires Authentication

A pilot study of new promising non-coding RNA diagnostic biomarkers for early-stage colorectal cancers

  • Hanshao Liu , Deji Ye , Aijun Chen , Dan Tan , Wenpeng Zhang , Wenxia Jiang , Mingliang Wang EMAIL logo and Xiaoren Zhang EMAIL logo
Published/Copyright: April 12, 2019
Clinical Chemistry and Laboratory Medicine (CCLM)
From the journal Clinical Chemistry and Laboratory Medicine (CCLM) Volume 57 Issue 7

Abstract

Background

Diagnostic biomarkers for the detection of colorectal cancers (CRCs) are lacking. Recent studies have demonstrated that circulating long non-coding RNAs have the potential to serve as biomarkers for the detection of cancers. We analyzed the significance of lncRNAs 91H, PVT-1 and MEG3 in the detection of CRC.

Methods

We examined the expression levels of 13 candidate lncRNAs in the plasma of 18 CRC patients and 20 non-cancerous controls. Then, we validated our findings by determining the expression levels of six promising lncRNAs in CRC tissues and normal colorectal tissues. Finally, we evaluated the clinical relevance of lncRNAs 91H, PVT-1 and MEG3 in the plasma of 58 CRC patients and 56 non-cancerous controls.

Results

Our data revealed that the expression levels of lncRNAs 91H, PVT-1 and MEG3 were significantly higher in plasma samples from CRC patients than in those from non-cancerous controls. The combination of 91H, PVT-1 and MEG3 could discriminate CRC patients from non-cancerous controls with an area under the receiver-operating curve (AUC) of 0.877 at a cut-off value of 0.3816, with a sensitivity of 82.76% and 78.57% specificity. More importantly, the combination of lncRNAs shows more sensitivity in the detection of early-stage CRC than the combination of CEA and CA19-9, biomarkers currently used for CRC detection (p < 0.0001).

Conclusions

lncRNAs 91H, PVT-1 and MEG3 are promising diagnostic biomarkers for early-stage CRC.

Keywords: biomarker; colorectal cancer; LncRNA; plasma
Corresponding author: Dr. Xiaoren Zhang, Cancer Hospital and Institute of Guangzhou Medical University, Guangzhou, P.R. China; General Surgery Department, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, P.R. China; and CAS Key Laboratory of Tissue Microenvironment and Tumor, Shanghai Institute of Nutrition and Health, Shanghai Institutes for Biological Sciences, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Room 1126, Biological Research Building A, 320 Yueyang Road, Shanghai 200025, P.R. China, Phone: +86-21-54920601, Fax: +86-21-54920601
aHanshao Liu, Deji Ye and Aijun Chen contributed equally to this work.

Funding source: National Program on Key Research

Award Identifier / Grant number: 2016YFC1302400

Funding source: National Basic Research Program

Award Identifier / Grant number: 2014CB541904

Award Identifier / Grant number: 2014CB943600

Funding source: National Natural Science Foundation of China

Award Identifier / Grant number: 91742113

Award Identifier / Grant number: 31570902

Award Identifier / Grant number: 31370881

Funding source: Natural Science Foundation of Shanghai

Award Identifier / Grant number: 14ZR1426300

Award Identifier / Grant number: 18ZR1446400

Funding statement: This work was supported by the National Program on Key Research (2016YFC1302400), the National Basic Research Program (2014CB541904, 2014CB943600), National Natural Science Foundation of China (Funder Id: http://dx.doi.org/10.13039/501100001809, 91742113, Funder Id: http://dx.doi.org/10.13039/501100001809, 31570902, Funder Id: http://dx.doi.org/10.13039/501100001809, 31370881), and Natural Science Foundation of Shanghai (14ZR1426300, 18ZR1446400).

  1. Author contributions: Conception and design: X. Zhang, H. Liu, M. Wang. Development of methodology: H. Liu. Acquisition of data (e.g. provided animals, acquired and managed patients, provided facilities, etc.): A. Chen, H. Liu, D. Ye, D. Tan. Analysis and interpretation of data (e.g. statistical analysis, biostatistics, computational analysis): H. Liu, D. Ye. Writing, review and/or revision of the manuscript: H. Liu, X. Zhang, M Wang, D. Ye. Administrative, technical, or material support (i.e. reporting or organizing data, constructing databases): X. Zhang, M. Wang, H. Liu. Study supervision: X. Zhang, M Wang. All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.

  2. Employment or leadership: None declared.

  3. Honorarium: None declared.

  4. Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.

References

1. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. GLOBOCAN 2012 v1.0, cancer incidence and mortality worldwide: IARC cancer base no. 11. Lyon, France: International Agency for Research on Cancer, 2013.Search in Google Scholar

2. Arnold M, Sierra MS, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global patterns and trends in colorectal cancer incidence and mortality. Gut 2017;66:683–91.10.1136/gutjnl-2015-310912Search in Google Scholar

3. Center MM, Jemal A, Smith RA, Ward E. Worldwide variations in colorectal cancer. CA Cancer J Clin 2009;59:366–78.10.3322/caac.20038Search in Google Scholar

4. Zhang Y, Shi J, Huang H, Ren J, Li N, Dai M. [Burden of colorectal cancer in China]. Zhonghua Liu Xing Bing Xue Za Zhi 2015;36:709–14.Search in Google Scholar

5. Figueredo A, Coombes ME, Mukherjee S. Adjuvant therapy for completely resected stage II colon cancer. Cochrane Database Syst Rev 2008;16:CD005390.10.1002/14651858.CD005390Search in Google Scholar

6. Lim YK, Kam MH, Eu KW. Carcinoembryonic antigen screening: how far should we go? Singapore Med J 2009;50:862–5.Search in Google Scholar

7. Duffy MJ, van Dalen A, Haglund C, Hansson L, Klapdor R, Lamerz R, et al. Clinical utility of biochemical markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines. Eur J Cancer 2003;39:718–27.10.1016/S0959-8049(02)00811-0Search in Google Scholar

8. Church TR, Wandell M, Lofton-Day C, Mongin SJ, Burger M, Payne SR, et al. Prospective evaluation of methylated SEPT9 in plasma for detection of asymptomatic colorectal cancer. Gut 2014;63:317–25.10.1136/gutjnl-2012-304149Search in Google Scholar PubMed PubMed Central

9. Molnar B, Toth K, Bartak BK, Tulassay Z. Plasma methylated septin 9: a colorectal cancer screening marker. Expert Rev Mol Diagn 2015;15:171–84.10.1586/14737159.2015.975212Search in Google Scholar PubMed

10. Ponting CP, Oliver PL, Reik W. Evolution and functions of long noncoding RNAs. Cell 2009;136:629–41.10.1016/j.cell.2009.02.006Search in Google Scholar PubMed

11. Guttman M, Amit I, Garber M, French C, Lin MF, Feldser D, et al. Chromatin signature reveals over a thousand highly conserved large non-coding RNAs in mammals. Nature 2009;458:223–7.10.1038/nature07672Search in Google Scholar PubMed PubMed Central

12. Cabili MN, Trapnell C, Goff L, Koziol M, Tazon-Vega B, Regev A, et al. Integrative annotation of human large intergenic noncoding RNAs reveals global properties and specific subclasses. Genes Dev 2011;25:1915–27.10.1101/gad.17446611Search in Google Scholar PubMed PubMed Central

13. Orom UA, Derrien T, Beringer M, Gumireddy K, Gardini A,Bussotti G, et al. Long noncoding RNAs with enhancer-like function in human cells. Cell 2010;143:46–58.10.1016/j.cell.2010.09.001Search in Google Scholar PubMed PubMed Central

14. Sigova AA, Abraham BJ, Ji X, Molinie B, Hannett NM, Guo YE, et al. Transcription factor trapping by RNA in gene regulatory elements. Science 2015;350:978–81.10.1126/science.aad3346Search in Google Scholar PubMed PubMed Central

15. Khalil AM, Guttman M, Huarte M, Garber M, Raj A, Rivea Morales D, et al. Many human large intergenic noncoding RNAs associate with chromatin-modifying complexes and affect gene expression. Proc Natl Acad Sci USA 2009;106:11667–72.10.1073/pnas.0904715106Search in Google Scholar PubMed PubMed Central

16. Tsai MC, Manor O, Wan Y, Mosammaparast N, Wang JK, Lan F, et al. Long noncoding RNA as modular scaffold of histone modification complexes. Science 2010;329:689–93.10.1126/science.1192002Search in Google Scholar PubMed PubMed Central

17. Zhang K, Shi H, Xi H, Wu X, Cui J, Gao Y, et al. Genome-wide lncRNA microarray profiling identifies novel circulating lncRNAs for detection of gastric cancer. Theranostics 2017;7:213–27.10.7150/thno.16044Search in Google Scholar PubMed PubMed Central

18. Yan X, Hu Z, Feng Y, Hu X, Yuan J, Zhao SD, et al. Comprehensive genomic characterization of long non-coding RNAs across human cancers. Cancer Cell 2015;28:529–40.10.1016/j.ccell.2015.09.006Search in Google Scholar PubMed PubMed Central

19. Tong YS, Wang XW, Zhou XL, Liu ZH, Yang TX, Shi WH, et al. Identification of the long non-coding RNA POU3F3 in plasma as a novel biomarker for diagnosis of esophageal squamous cell carcinoma. Mol Cancer 2015;14:3.10.1186/1476-4598-14-3Search in Google Scholar PubMed PubMed Central

20. Bussemakers MJ, van Bokhoven A, Verhaegh GW, Smit FP, Karthaus HF, Schalken JA, et al. DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res 1999;59:5975–9.Search in Google Scholar

21. Zhou X, Yin C, Dang Y, Ye F, Zhang G. Identification of the long non-coding RNA H19 in plasma as a novel biomarker for diagnosis of gastric cancer. Sci Rep 2015;5:11516.10.1038/srep11516Search in Google Scholar PubMed PubMed Central

22. Svoboda M, Slyskova J, Schneiderova M, Makovicky P, Bielik L, Levy M, et al. HOTAIR long non-coding RNA is a negative prognostic factor not only in primary tumors, but also in the blood of colorectal cancer patients. Carcinogenesis 2014;35:1510–5.10.1093/carcin/bgu055Search in Google Scholar PubMed

23. Panzitt K, Tschernatsch MM, Guelly C, Moustafa T, Stradner M, Strohmaier HM, et al. Characterization of HULC, a novel gene with striking up-regulation in hepatocellular carcinoma, as noncoding RNA. Gastroenterology 2007;132:330–42.10.1053/j.gastro.2006.08.026Search in Google Scholar PubMed

24. Hu X, Bao J, Wang Z, Zhang Z, Gu P, Tao F, et al. The plasma lncRNA acting as fingerprint in non-small-cell lung cancer. Tumour Biol 2016;37:3497–504.10.1007/s13277-015-4023-9Search in Google Scholar PubMed

25. Yin DD, Liu ZJ, Zhang E, Kong R, Zhang ZH, Guo RH. Decreased expression of long noncoding RNA MEG3 affects cell proliferation and predicts a poor prognosis in patients with colorectal cancer. Tumour Biol 2015;36:4851–9.10.1007/s13277-015-3139-2Search in Google Scholar PubMed

26. Zheng HT, Shi DB, Wang YW, Li XX, Xu Y, Tripathi P, et al. High expression of lncRNA MALAT1 suggests a biomarker of poor prognosis in colorectal cancer. Int J Clin Exp Pathol 2014;7:3174–81.Search in Google Scholar

27. Takahashi Y, Sawada G, Kurashige J, Uchi R, Matsumura T, Ueo H, et al. Amplification of PVT-1 is involved in poor prognosis via apoptosis inhibition in colorectal cancers. Br J Cancer 2014;110:164–71.10.1038/bjc.2013.698Search in Google Scholar PubMed PubMed Central

28. Han Y, Yang YN, Yuan HH, Zhang TT, Sui H, Wei XL, et al. UCA1, a long non-coding RNA up-regulated in colorectal cancer influences cell proliferation, apoptosis and cell cycle distribution. Pathology 2014;46:396–401.10.1097/PAT.0000000000000125Search in Google Scholar PubMed

29. Han D, Gao X, Wang M, Qiao Y, Xu Y, Yang J, et al. Long noncoding RNA H19 indicates a poor prognosis of colorectal cancer and promotes tumor growth by recruiting and binding to eIF4A3. Oncotarget 2016;7:22159–73.10.18632/oncotarget.8063Search in Google Scholar PubMed PubMed Central

30. Park J, Jeong S. Wnt activated beta-catenin and YAP proteins enhance the expression of non-coding RNA component of RNase MRP in colon cancer cells. Oncotarget 2015;6:34658–68.10.18632/oncotarget.5778Search in Google Scholar PubMed PubMed Central

31. Wu Y, Yang L, Zhao J, Li C, Nie J, Liu F, et al. Nuclear-enriched abundant transcript 1 as a diagnostic and prognostic biomarker in colorectal cancer. Mol Cancer 2015;14:191.10.1186/s12943-015-0455-5Search in Google Scholar PubMed PubMed Central

32. Li Y, Li Y, Chen W, He F, Tan Z, Zheng J, et al. NEAT expression is associated with tumor recurrence and unfavorable prognosis in colorectal cancer. Oncotarget 2015;6:27641–50.10.18632/oncotarget.4737Search in Google Scholar PubMed PubMed Central

33. Xiang JF, Yin QF, Chen T, Zhang Y, Zhang XO, Wu Z, et al. Human colorectal cancer-specific CCAT1-L lncRNA regulates long-range chromatin interactions at the MYC locus. Cell Res 2014;24:513–31.10.1038/cr.2014.35Search in Google Scholar PubMed PubMed Central

34. Ling H, Spizzo R, Atlasi Y, Nicoloso M, Shimizu M, Redis RS, et al. CCAT2, a novel noncoding RNA mapping to 8q24, underlies metastatic progression and chromosomal instability in colon cancer. Genome Res 2013;23:1446–61.10.1101/gr.152942.112Search in Google Scholar PubMed PubMed Central

35. Deng Q, He B, Gao T, Pan Y, Sun H, Xu Y, et al. Up-regulation of 91H promotes tumor metastasis and predicts poor prognosis for patients with colorectal cancer. PLoS One 2014;9:e103022.10.1371/journal.pone.0103022Search in Google Scholar PubMed PubMed Central

36. Yin D, He X, Zhang E, Kong R, De W, Zhang Z. Long noncoding RNA GAS5 affects cell proliferation and predicts a poor prognosis in patients with colorectal cancer. Med Oncol 2014;31:253.10.1007/s12032-014-0253-8Search in Google Scholar PubMed

37. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc 2008;3:1101–8.10.1038/nprot.2008.73Search in Google Scholar PubMed

38. Han L, Ma P, Liu SM, Zhou X. Circulating long noncoding RNA GAS5 as a potential biomarker in breast cancer for assessing the surgical effects. Tumour Biol 2016;37:6847–54.10.1007/s13277-015-4568-7Search in Google Scholar PubMed

39. Li L, Zhang GQ, Chen H, Zhao ZJ, Chen HZ, Liu H, et al. Plasma and tumor levels of Linc-pint are diagnostic and prognostic biomarkers for pancreatic cancer. Oncotarget 2016;7:71773–81.10.18632/oncotarget.12365Search in Google Scholar PubMed PubMed Central

40. Wan L, Kong J, Tang J, Wu Y, Xu E, Lai M, et al. HOTAIRM1 as a potential biomarker for diagnosis of colorectal cancer functions the role in the tumour suppressor. J Cell Mol Med 2016;20:2036–44.10.1111/jcmm.12892Search in Google Scholar PubMed PubMed Central

41. Dong L, Qi P, Xu MD, Ni SJ, Huang D, Xu QH, et al. Circulating CUDR, LSINCT-5 and PTENP1 long noncoding RNAs in sera distinguish patients with gastric cancer from healthy controls. Int J Cancer 2015;137:1128–35.10.1002/ijc.29484Search in Google Scholar PubMed

42. Kogo R, Shimamura T, Mimori K, Kawahara K, Imoto S, Sudo T, et al. Long noncoding RNA HOTAIR regulates polycomb-dependent chromatin modification and is associated with poor prognosis in colorectal cancers. Cancer Res 2011;71:6320–6.10.1158/0008-5472.CAN-11-1021Search in Google Scholar PubMed

43. Zhao W, Song M, Zhang J, Kuerban M, Wang H. Combined identification of long non-coding RNA CCAT1 and HOTAIR in serum as an effective screening for colorectal carcinoma. Int J Clin Exp Pathol 2015;8:14131–40.Search in Google Scholar

44. Vasaikar SV, Straub P, Wang J, Zhang B. LinkedOmics: analyzing multi-omics data within and across 32 cancer types. Nucleic Acids Res 2018;46:D956–D63.10.1093/nar/gkx1090Search in Google Scholar PubMed PubMed Central

45. Gao T, Liu X, He B, Nie Z, Zhu C, Zhang P, et al. Exosomal lncRNA 91H is associated with poor development in colorectal cancer by modifying HNRNPK expression. Cancer Cell Int 2018;18:11.10.1186/s12935-018-0506-2Search in Google Scholar PubMed PubMed Central

46. Schmitt AM, Chang HY. Long noncoding RNAs in cancer pathways. Cancer Cell 2016;29:452–63.10.1016/j.ccell.2016.03.010Search in Google Scholar PubMed PubMed Central

47. Tokunaga R, Sakamoto Y, Nakagawa S, Yoshida N, Baba H. The utility of tumor marker combination, including serum P53 antibody, in colorectal cancer treatment. Surg Today 2017;47:636–42.10.1007/s00595-016-1464-8Search in Google Scholar PubMed

48. Yamashita K, Watanabe M. Clinical significance of tumor markers and an emerging perspective on colorectal cancer. Cancer Sci 2009;100:195–9.10.1111/j.1349-7006.2008.01022.xSearch in Google Scholar PubMed

49. Gonzalez-Pons M, Cruz-Correa M. Colorectal cancer biomarkers: where are we now? BioMed Res Int 2015;2015:149014.10.1155/2015/149014Search in Google Scholar PubMed PubMed Central

50. Berteaux N, Aptel N, Cathala G, Genton C, Coll J, Daccache A, et al. A novel H19 antisense RNA overexpressed in breast cancer contributes to paternal IGF2 expression. Mol Cell Biol 2008;28:6731–45.10.1128/MCB.02103-07Search in Google Scholar PubMed PubMed Central

51. Vennin C, Spruyt N, Robin YM, Chassat T, Le Bourhis X, Adriaenssens E. The long non-coding RNA 91H increases aggressive phenotype of breast cancer cells and up-regulates H19/IGF2 expression through epigenetic modifications. Cancer Lett 2017;385:198–206.10.1016/j.canlet.2016.10.023Search in Google Scholar PubMed

52. Braconi C, Kogure T, Valeri N, Huang N, Nuovo G, Costinean S, et al. microRNA-29 can regulate expression of the long non-coding RNA gene MEG3 in hepatocellular cancer. Oncogene 2011;30:4750–6.10.1038/onc.2011.193Search in Google Scholar PubMed PubMed Central

53. Lyu Y, Lou J, Yang Y, Feng J, Hao Y, Huang S, et al. Dysfunction of the WT1-MEG3 signaling promotes AML leukemogenesis via p53-dependent and -independent pathways. Leukemia 2017;31:2543–51.10.1038/leu.2017.116Search in Google Scholar PubMed PubMed Central

54. Mondal T, Subhash S, Vaid R, Enroth S, Uday S, Reinius B, et al. MEG3 long noncoding RNA regulates the TGF-beta pathway genes through formation of RNA-DNA triplex structures. Nat Commun 2015;6:7743.10.1038/ncomms8743Search in Google Scholar PubMed PubMed Central

55. Cao X, Zhuang S, Hu Y, Xi L, Deng L, Sheng H, et al. Associations between polymorphisms of long non-coding RNA MEG3 and risk of colorectal cancer in Chinese. Oncotarget 2016;7:19054–9.10.18632/oncotarget.7764Search in Google Scholar PubMed PubMed Central

56. Liu H, Zhu L, Liu B, Yang L, Meng X, Zhang W, et al. Genome-wide microRNA profiles identify miR-378 as a serum biomarker for early detection of gastric cancer. Cancer Lett 2012;316:196–203.10.1016/j.canlet.2011.10.034Search in Google Scholar PubMed

57. Pigati L, Yaddanapudi SC, Iyengar R, Kim DJ, Hearn SA, Danforth D, et al. Selective release of microRNA species from normal and malignant mammary epithelial cells. PLoS One 2010;5:e13515.10.1371/journal.pone.0013515Search in Google Scholar PubMed PubMed Central

58. Li D, Chen G, Yang J, Fan X, Gong Y, Xu G, et al. Transcriptome analysis reveals distinct patterns of long noncoding RNAs in heart and plasma of mice with heart failure. PLoS One 2013;8:e77938.10.1371/journal.pone.0077938Search in Google Scholar PubMed PubMed Central

Supplementary Material

The online version of this article offers supplementary material (https://doi.org/10.1515/cclm-2019-0052).

Received: 2019-01-15
Accepted: 2019-03-12
Published Online: 2019-04-12
Published in Print: 2019-06-26

©2019 Walter de Gruyter GmbH, Berlin/Boston

Articles in the same Issue

  1. Frontmatter
  2. Editorial
  3. Epigenetics in cancer: a promising path to follow?
  4. Reviews
  5. The circulating miRNAs as diagnostic and prognostic markers
  6. Analytical barriers in clinical B-type natriuretic peptide measurement and the promising analytical methods based on mass spectrometry technology
  7. Mini Review
  8. Commutability of reference and control materials: an essential factor for assuring the quality of measurements in Laboratory Medicine
  9. EFLM Paper
  10. Preanalytical challenges – time for solutions
  11. General Clinical Chemistry and Laboratory Medicine
  12. Iron status determination in individuals with Helicobacter pylori infection: conventional vs. new laboratory biomarkers
  13. Harmonizing by reducing inter-run variability: performance evaluation of a quality assurance program for antinuclear antibody detection by indirect immunofluorescence
  14. Increased prevalence of anti-DFS70 antibodies in young females: experience from a large international multi-center study on blood donors
  15. Accuracy of determination of the glomerular filtration marker iohexol by European laboratories as monitored by external quality assessment
  16. Therapeutic drug monitoring (TDM) of 5-fluorouracil (5-FU): new preanalytic aspects
  17. Monitoring the effectiveness of hypothermia in perinatal asphyxia infants by urinary S100B levels
  18. Hematology and Coagulation
  19. Determination of haemoglobin derivatives in aged dried blood spot to estimate haematocrit
  20. Reference Values and Biological Variations
  21. A study of biological and lifestyle factors, including within-subject variation, affecting concentrations of growth differentiation factor 15 in serum
  22. Reference intervals for thyroid-stimulating hormone, free thyroxine, and free triiodothyronine in elderly Chinese persons
  23. Cancer Diagnostics
  24. Extracellular vesicle-associated miRNAs in ovarian cancer – design of an integrated NGS-based workflow for the identification of blood-based biomarkers for platinum-resistance
  25. Evaluating the diagnostic and prognostic value of serum long non-coding RNA CTC-497E21.4 in gastric cancer
  26. A pilot study of new promising non-coding RNA diagnostic biomarkers for early-stage colorectal cancers
  27. Cardiovascular Diseases
  28. Prognostic role of GDF-15 across the spectrum of clinical risk in patients with NSTE-ACS
  29. Acute-phase dynamics and prognostic value of growth differentiation factor-15 in ST-elevation myocardial infarction
  30. Diabetes
  31. Lipid profile and genetic status in a familial hypercholesterolemia pediatric population: exploring the LDL/HDL ratio
  32. Letters to the Editor
  33. The search for a new test of early cancer detection
  34. Need of a dedicated isotopic internal standard for accurate 3-epi-25(OH)D3 quantification by LC-MS/MS
  35. An unexpectedly prolonged severe hyperbilirubinemia in a patient with pre-existing hepatitis A: a role of genetic predisposition?
  36. Creatine kinase elevation: a neglected clue to the diagnosis of polymyositis. A case report
  37. Analytical performance of the new Siemens NT-proBNP assays on the Advia Centaur XPT compared to the NT-proBNP method on the Dimension Vista
  38. Free PAPP-A as a biomarker: heparin-induced release is not related to coronary atherosclerotic burden
  39. Anti-citrullinated protein antibodies are not associated with extent of disease or prognosis in patients with coronary artery disease
  40. A new preanalytical factor: conveyor transport influences residual platelet concentrations
  41. Stability of cannabinoids in cannabis FM1 flowering tops and oil preparation evaluated by ultra-high performance liquid chromatography tandem mass spectrometry
  42. Requirement of a reference measurement system for the tissue factor-induced coagulation time and the international normalized ratio
https://doi.org/10.1515/cclm-2019-0052
Keywords for this article
biomarker; colorectal cancer; LncRNA; plasma

Articles in the same Issue

  1. Frontmatter
  2. Editorial
  3. Epigenetics in cancer: a promising path to follow?
  4. Reviews
  5. The circulating miRNAs as diagnostic and prognostic markers
  6. Analytical barriers in clinical B-type natriuretic peptide measurement and the promising analytical methods based on mass spectrometry technology
  7. Mini Review
  8. Commutability of reference and control materials: an essential factor for assuring the quality of measurements in Laboratory Medicine
  9. EFLM Paper
  10. Preanalytical challenges – time for solutions
  11. General Clinical Chemistry and Laboratory Medicine
  12. Iron status determination in individuals with Helicobacter pylori infection: conventional vs. new laboratory biomarkers
  13. Harmonizing by reducing inter-run variability: performance evaluation of a quality assurance program for antinuclear antibody detection by indirect immunofluorescence
  14. Increased prevalence of anti-DFS70 antibodies in young females: experience from a large international multi-center study on blood donors
  15. Accuracy of determination of the glomerular filtration marker iohexol by European laboratories as monitored by external quality assessment
  16. Therapeutic drug monitoring (TDM) of 5-fluorouracil (5-FU): new preanalytic aspects
  17. Monitoring the effectiveness of hypothermia in perinatal asphyxia infants by urinary S100B levels
  18. Hematology and Coagulation
  19. Determination of haemoglobin derivatives in aged dried blood spot to estimate haematocrit
  20. Reference Values and Biological Variations
  21. A study of biological and lifestyle factors, including within-subject variation, affecting concentrations of growth differentiation factor 15 in serum
  22. Reference intervals for thyroid-stimulating hormone, free thyroxine, and free triiodothyronine in elderly Chinese persons
  23. Cancer Diagnostics
  24. Extracellular vesicle-associated miRNAs in ovarian cancer – design of an integrated NGS-based workflow for the identification of blood-based biomarkers for platinum-resistance
  25. Evaluating the diagnostic and prognostic value of serum long non-coding RNA CTC-497E21.4 in gastric cancer
  26. A pilot study of new promising non-coding RNA diagnostic biomarkers for early-stage colorectal cancers
  27. Cardiovascular Diseases
  28. Prognostic role of GDF-15 across the spectrum of clinical risk in patients with NSTE-ACS
  29. Acute-phase dynamics and prognostic value of growth differentiation factor-15 in ST-elevation myocardial infarction
  30. Diabetes
  31. Lipid profile and genetic status in a familial hypercholesterolemia pediatric population: exploring the LDL/HDL ratio
  32. Letters to the Editor
  33. The search for a new test of early cancer detection
  34. Need of a dedicated isotopic internal standard for accurate 3-epi-25(OH)D3 quantification by LC-MS/MS
  35. An unexpectedly prolonged severe hyperbilirubinemia in a patient with pre-existing hepatitis A: a role of genetic predisposition?
  36. Creatine kinase elevation: a neglected clue to the diagnosis of polymyositis. A case report
  37. Analytical performance of the new Siemens NT-proBNP assays on the Advia Centaur XPT compared to the NT-proBNP method on the Dimension Vista
  38. Free PAPP-A as a biomarker: heparin-induced release is not related to coronary atherosclerotic burden
  39. Anti-citrullinated protein antibodies are not associated with extent of disease or prognosis in patients with coronary artery disease
  40. A new preanalytical factor: conveyor transport influences residual platelet concentrations
  41. Stability of cannabinoids in cannabis FM1 flowering tops and oil preparation evaluated by ultra-high performance liquid chromatography tandem mass spectrometry
  42. Requirement of a reference measurement system for the tissue factor-induced coagulation time and the international normalized ratio
Sign up now to receive a 20% welcome discount
Institutional Access
How does access work?
Winner of the OpenAthens UX Award 2026
Winner of the OpenAthens UX Award 2026
Have an idea on how to improve our website?
Please write us.
© 2026 De Gruyter Brill
Downloaded on 12.3.2026 from https://www.degruyterbrill.com/document/doi/10.1515/cclm-2019-0052/html
Scroll to top button